Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 70
Selected: 0
NCT IDTitle
NCT02456701Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
NCT03835533Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
NCT06650761A Phase I Study of CDX-622
NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT00704158Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
NCT04536077Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
NCT02413827A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
NCT01094496A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
NCT03580382Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
NCT01997333Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
NCT02924038A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
NCT00323518A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
NCT00709462A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
NCT00948961A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
NCT01156753A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT02837991A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
NCT00648102Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
NCT05788484A Study of CDX-585 in Patients With Advanced Malignancies
NCT02200380A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
NCT05368285A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT03688178DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
NCT01480479Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT02839265FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
NCT04538794A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT06727552A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT01460134A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT04364230Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
NCT00412828A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
NCT02284971Pilot Study of SBRT and CDX-1127 in Prostate Cancer
NCT02713828Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
NCT00458601Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
NCT01498328A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT03804944Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT02543645A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT01976585In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
NCT03473691Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
NCT04491084FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
NCT06366750A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT04440943A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT02473731A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
NCT02270372Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
NCT02302339A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
NCT04944862A Study of CDX-0159 in Patients With Prurigo Nodularis
NCT01465139A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
NCT04548869A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
NCT00104065Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
NCT05484011A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT01791686Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
NCT05405660A Study of CDX-0159 in Patients With Chronic Inducible Urticaria